Total amount: € 0,00
HOW TO ORDER
A Journal on Otorhinolaryngology, Head and Neck Surgery,
Plastic Reconstructive Surgery, Otoneurosurgery
Indexed/Abstracted in: EMBASE, Scopus
Otorinolaringologia 1999 June;49(2):103-6
Cefetamet Pivoxil in the treatment of acute otitis media and externa
Farri A., Enrico A., Cammarota R.
Università degli Studi - Torino I Clinica ORL
Background. The study aimed to evaluate the clinical efficacy of antibiotic treatment of otitis media and externa using Cefetamet Pivoxil (3rd generation cephalosporine with a wide antibacterial spectrum).
Methods. An experimental study was performed from January to July 1997 in a random sample of 55 patients (32 males and 23 females, mean age 37.5 years) suffering from otitis media; 21 subjects also presented associated symptoms of otitis externa. The therapeutic protocol specified the use of Cefetamet Pivoxil for at least 8 days at an age-related dose; in adults and children over 12, the standard dose was 500 mg twice a day; in younger children the standard dose of 10 mg/kg was divided into two daily administrations. All patients were supervised by the authors throughout the treatment period. The patients were re-examined at the end of treatment, approximately one week after the first check-up. The clinical efficacy of antibiotic therapy was evaluated according to three levels of response: +, ++ and +++, depending on the degree of improvement achieved.
Results. Clinical recovery (+++) was observed in 52.7% of patients. A marked improvement in symptoms and objective clinical status (++) was reported in 36.3% of the population, whereas only 9% of the sample showed slight therapeutic benefits (+).
Conclusions. Cefetamet Pivoxil is a drug that is reliable and well tolerated (in 98.2% of cases), and represents a valid alternative to the drugs now used as the elective form of treatment.